Literature DB >> 24606571

Trends in door-to-balloon time and outcomes following primary percutaneous coronary intervention for ST-elevation myocardial infarction: an Australian perspective.

A L Brennan1, N Andrianopoulos, S J Duffy, C M Reid, D J Clark, P Loane, G New, A Black, B P Yan, M Brooks, L Roberts, E A Carroll, J Lefkovits, A E Ajani.   

Abstract

BACKGROUND: Guidelines for patients with ST-elevation myocardial infarction include a door-to-balloon time (DTBT) of ≤90 min for primary percutaneous coronary intervention. AIM: The aim of this study was to assess temporal trends (2006-2010) in DTBT and determine if a reduction in DTBT was associated with improved clinical outcomes.
METHODS: We compared annual median DTBT in 1926 STEMI patients undergoing primary percutaneous coronary intervention from the Melbourne Interventional Group registry. ST-elevation myocardial infarction presenting >12 h and rescue percutaneous coronary intervention was excluded. Major adverse cardiac events were analysed according to DTBT (dichotomised as ≤90 min vs >90 min). A multivariable analysis for predictors of mortality (including DTBT) was performed.
RESULTS: Baseline demographics, clinical and procedural characteristics were similar in the STEMI cohort across the 5 years, apart from an increase in out-of-hospital cardiac arrest (3.6% in 2006 vs 9.4% in 2010, P < 0.0001) and cardiogenic shock (7.7-9.6%, P = 0.07). The median DTBT (interquartile range) was reduced from 95 (74-130) min in 2006 to 75 (51-100) min in 2010 (P < 0.01). In this period, the proportion of patients achieving a DTBT of ≤90 min increased from 45% to 67% (P < 0.01). Lower mortality and major adverse cardiac event rates were observed with DTBT ≤90 min (all P < 0.01). Multivariable analysis showed that a DTBT of ≤90 min was associated with improved clinical outcomes at 12 months (odds ratio 0.48; 95% confidence interval 0.33-0.73, P < 0.01).
CONCLUSION: There has been a decline in median DTBT in the Melbourne Interventional Group registry over 5 years. DTBT of ≤90 min is associated with improved clinical outcomes at 12 months.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  ST-elevation myocardial infarction; clinical outcome; door-to-balloon time; primary percutaneous coronary intervention; trend

Mesh:

Substances:

Year:  2014        PMID: 24606571     DOI: 10.1111/imj.12405

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

1.  Development of a Catheterization and Percutaneous Coronary Intervention Registry with a Data Management Approach: A Systematic Review.

Authors:  Alireza Tabatabaei Tabrizi; Hamid Moghaddasi; Reza Rabiei; Babak Sharif-Kashani; And Eslam Nazemi
Journal:  Perspect Health Inf Manag       Date:  2019-01-01

2.  The effect of door-to-balloon delay in primary percutaneous coronary intervention on clinical outcomes of STEMI: a systematic review and meta-analysis protocol.

Authors:  Chee Yoong Foo; Daniel D Reidpath; Nathorn Chaiyakunapruk
Journal:  Syst Rev       Date:  2016-08-02

3.  Association between the Door-to-balloon Time and Mid-term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Takunori Tsukui; Kenichi Sakakura; Yousuke Taniguchi; Kei Yamamoto; Masaru Seguchi; Hiroshi Wada; Shin-Ichi Momomura; Hideo Fujita
Journal:  Intern Med       Date:  2020-07-01       Impact factor: 1.271

4.  Close, but not close enough.

Authors:  J Daemen
Journal:  Neth Heart J       Date:  2014-11       Impact factor: 2.380

5.  Door-in to door-out times in acute ST-segment elevation myocardial infarction in emergency departments of non-interventional hospitals: A cohort study.

Authors:  Sandrine Clot; Thomas Rocher; Claire Morvan; Mathieu Cardine; Mohamed Lotfi; Julien Turk; Pascal Usseglio; Vincent Descotes-Genon; Gerald Vanzetto; Dominique Savary; Guillaume Debaty; Loic Belle
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.